Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Wockhardt wins FDA approval for Zaynich as #WOCKPHARMA nears 52-week high
Wockhardt Limited’s Zaynich FDA approval could reshape its antibiotic pipeline story. Find out what it means for investors and Indian pharma.
Anlon Healthcare FY26 results: AHCL revenue jumps 43% as acquisitions reshape API growth strategy
Anlon Healthcare is scaling APIs, CDMO work and acquisitions after sharp FY26 growth. Read why AHCL’s next test is execution.
Avacta Therapeutics (AIM: AVCT) names Richard Hughes chairman as Shaun Chilton steps back
Avacta hands the chair to dealmaker Richard Hughes and adds a biotech deputy, a boardroom rebuild aimed squarely at pharma partnering. Read more.
Why oncology clinicians are watching EOM613’s effect on muscle loss, appetite, and chemotherapy readiness
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
How the TIGeR-PaC sub-study could influence future thinking around chemotherapy tolerability and precision delivery
RenovoRx’s TIGeR-PaC sub-study highlights how targeted chemotherapy delivery could reshape pancreatic cancer treatment strategy. Read more.
Rocket One (NASDAQ: RKTO) debuts with AMD program win as biotech pivots to orbital AI chips
A no-revenue biotech rebranded into AI-space chips and ran 60% on debut. The AMD link is real, but so is the cash burn and the looming dilution.
How Johns Hopkins IRB approval strengthens Clearmind Medicine’s clinical credibility in addiction medicine
Clearmind Medicine’s Johns Hopkins-backed CMND-100 trial expansion could reshape addiction therapeutics. Discover what industry observers are watching next.
Corcept Therapeutics (NASDAQ: CORT) climbs 7% as Lifyorli launch and analyst upgrades drive cortisol re-rating
Corcept turned a stress hormone into an ovarian cancer drug. Lifyorli is launching fast and analysts are chasing, but a premium multiple prices in a lot.
JW Therapeutics says China pharma deals remain insulated from Beijing’s sensitive technology scrutiny
JW Therapeutics says China pharma deals remain open despite Beijing tech scrutiny. See why biotech licensing still matters.
Is Eli Lilly (LLY) building the obesity drug supply chain nobody else can easily match?
Lilly’s obesity pipeline needs industrial muscle. Its $4.5bn Indiana bet shows why manufacturing may decide the next GLP-1 race.